- Home
- TNGX vs CHPT Comparison
TNGX vs CHPT Comparison
Compare TNGX & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- CHPT
- Stock Information
- Founded
- TNGX 2014
- CHPT 2007
- Country
- TNGX United States
- CHPT United States
- Employees
- TNGX N/A
- CHPT N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- CHPT Industrial Specialties
- Sector
- TNGX Health Care
- CHPT Consumer Discretionary
- Exchange
- TNGX Nasdaq
- CHPT Nasdaq
- Market Cap
- TNGX 351.2M
- CHPT 321.7M
- IPO Year
- TNGX N/A
- CHPT N/A
- Fundamental
- Price
- TNGX $5.16
- CHPT $0.68
- Analyst Decision
- TNGX Strong Buy
- CHPT Hold
- Analyst Count
- TNGX 6
- CHPT 10
- Target Price
- TNGX $12.20
- CHPT $1.46
- AVG Volume (30 Days)
- TNGX 3.9M
- CHPT 20.6M
- Earning Date
- TNGX 08-06-2025
- CHPT 06-04-2025
- Dividend Yield
- TNGX N/A
- CHPT N/A
- EPS Growth
- TNGX N/A
- CHPT N/A
- EPS
- TNGX N/A
- CHPT N/A
- Revenue
- TNGX $40,990,000.00
- CHPT $407,681,000.00
- Revenue This Year
- TNGX N/A
- CHPT $3.54
- Revenue Next Year
- TNGX N/A
- CHPT $26.21
- P/E Ratio
- TNGX N/A
- CHPT N/A
- Revenue Growth
- TNGX 10.09
- CHPT N/A
- 52 Week Low
- TNGX $1.03
- CHPT $0.51
- 52 Week High
- TNGX $12.02
- CHPT $2.44
- Technical
- Relative Strength Index (RSI)
- TNGX 79.99
- CHPT 48.12
- Support Level
- TNGX $4.40
- CHPT $0.67
- Resistance Level
- TNGX $5.37
- CHPT $0.87
- Average True Range (ATR)
- TNGX 0.65
- CHPT 0.07
- MACD
- TNGX 0.10
- CHPT -0.01
- Stochastic Oscillator
- TNGX 93.68
- CHPT 17.11
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.